You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復宏漢霖-B(02696.HK):HLX26用於實體瘤及淋巴瘤治療的臨試申請獲國家藥監局批准
格隆匯 04-15 17:03

格隆匯 4 月 15日丨復宏漢霖-B(02696.HK)宣佈,近日,公司自主研發的重組抗LAG-3人源化單克隆抗體注射液HLX26("HLX26")用於實體瘤及淋巴瘤治療的臨牀試驗申請獲國家藥品監督管理局("NMPA")批准。

HLX26為公司自主研發的靶向淋巴細胞活化基因3(Lymphocyte-activation

gene 3, LAG-3)胞外結構域的創新型人源化單克隆抗體,擬用於實體瘤及淋巴瘤治療。LAG-3主要表達在激活狀態的T細胞和部分NK細胞上,對T細胞的細胞增殖、活化和穩態起負調節作用。抑制LAG-3可以重新激活T細胞,恢復T細胞對腫瘤細胞的殺傷能力。HLX26通過阻斷LAG-3與其配體的相互作用,從而阻斷LAG-3介導的抑制T細胞功能的信號通路,恢復T細胞IL-2、IFN-γ等細胞因子的釋放,通過與公司自主開發的重組抗PD-1單克隆抗體注射液HLX10的聯用,在腫瘤微環境中阻斷免疫逃逸達到抑制腫瘤的目的。

臨牀前藥理學研究、藥代動力學研究及安全性評價證明,HLX26在體內外具有抗腫瘤作用,且具有良好的耐受性及安全性。同時,HLX26在與重組抗PD-1人源化單克隆抗體注射液HLX10的聯合用藥中顯示出更為顯著的抗腫瘤活性,具有協同效應。

截至公吿日,於全球範圍內尚無靶向LAG-3的藥品上市。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account